|Bid||0.00 x 90000|
|Ask||0.00 x 90000|
|Day's Range||89.25 - 90.57|
|52 Week Range||59.00 - 98.00|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||51.56|
|Forward Dividend & Yield||1.22 (1.37%)|
|Ex-Dividend Date||Oct 14, 2020|
|1y Target Est||N/A|
Abbott Laboratories (NYSE: ABT) has scored a fresh victory across the Atlantic Ocean. The company announced Monday that it has been granted a CE Mark for its MitraClip G4, the latest version of its popular heart valve replacement device, which means it is approved for use in the countries of the European Union. The G4 had already been approved for use in the U.S. by the Food and Drug Administration.
Deutsche Lufthansa AG plans to start making rapid COVID-19 antigen tests available to passengers in October and is weighing the option of opening test centres at airports in the United States and Canada, a company executive said on Tuesday. While the aviation industry has largely backed the use of Polymerase Chain Reaction (PCR) tests which take several hours to process in a lab, airline trade group IATA on Tuesday touted antigen tests that can be processed on site and typically give results within about 15 minutes. "You know that companies like Abbott or Roche are bringing these tests to the market and we are definitely looking into this," said Bjoern Becker, senior director, product management, ground & digital services for the Lufthansa Group.
Medical company Abbott has now launched a handful of coronavirus tests, and the U.S. is paying $750 million for 150 million of the most recently approved tests. So, is ABT stock a buy now?